TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

• Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction. 
• The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.
• According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.

Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.

Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.

A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.

Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”

Yet another user voiced optimism for good news while adding that they think it is “very close.”

Drug Approvals

The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.

The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.

Other Pipeline Updates

Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.

Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.

According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.

TNXP stock has dropped 52% over the past 12 months. 

Read More: ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

For updates and corrections, email newsroom[at]stocktwits[dot]com.